ACE and pachyonychia congenita: Given the relative strength and consistency of survival benefit associated with ARBs in our data, as compared with ACE inhibitors, it is tempting to prioritizing ARBs, such as losartan, for interventional studies in the general population of newly diagnosed PC patients.